ReviewFrontiers in oncology2025
Application and recent advances in conventional biomarkers for the prognosis of papillary thyroid carcinoma.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- Hsa_circ_0002111 implicates KTC-1 cell motility and modulates migration and invasion via miR-432-5p/CDKN2B axis.Scientific reports · 2026Article
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- Ultrasound radiomics for preoperative evaluation of Ki-67 proliferation index in papillary thyroid carcinoma.Frontiers in oncology · 2026Article
- Prognostic impact of RAS mutation on papillary thyroid carcinoma: a systematic review and meta-analysis.Thyroid research · 2025Review
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy.Pharmaceutics · 2025Review
- Histopathological, Immunohistochemical, Molecular and Genetic Biomarkers in Differentiated Thyroid Cancer.Cancers · 2025Review
- Nomogram model based on ultrasonography and contrast-enhanced CT for predicting BRAFFrontiers in endocrinology · 2025Article
- Mutation interactions of BRAF and TP53 define novel prognostic stratification and therapeutic implications in papillary thyroid carcinoma.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the most common and deadliest diseases worldwide. Among endocrine neoplasms, the incidence of thyroid malignancies has been rising in recent years. Papillary thyroid carcinoma (PTC), the most frequently observed histological subtype of thyroid cancer (THCA), typically yields favorable clinical outcomes for affected individuals. However, this has raised concerns about the overdiagnosis and underdetermination of the prognostic factors in PTC cases. As a result, researchers now advocate for patient stratification and tailored therapeutic approaches for PTC cases, with the goal of minimizing unnecessary surgical procedures and radioiodine treatments. These treatments can lead to clinical complications and impose avoidable physiological and psychological stress on patients. Multiple prognostic biomarkers have been identified for PTC, which play a critical role in predicting outcomes and informing treatment decisions. This review examines both established molecular tools and recent advancements in the determination of prognosis in in papillary thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.